Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProCervix for HPV 16/18 Clearance
NCT01957878Phase 2Completed
- Sponsor
- Genticel
- Start
- Dec 2013
- Primary completion
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of GTL001 in human papillomavirus infection (2 arms), sponsored by Genticel. Primary endpoint: Clearance of HPV 16 and HPV 18 infection at 12 months. Started Dec 2013; status: completed.
02
Drugs
GTL001
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01957878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01957878.